YERVOY
200mgYERVOY200mg
YERVOY (ipilimumab) 200mg is a groundbreaking CTLA-4 checkpoint inhibitor that pioneered cancer immunotherapy, used for melanoma and in combination with OPDIVO for multiple cancers.
Key Benefits
- Pioneered modern cancer immunotherapy
- CTLA-4 checkpoint inhibitor with proven efficacy
- Durable responses lasting years in some patients
- Synergistic with PD-1 inhibitors (OPDIVO)
- Multiple approved cancer indications
- Authentic Bristol Myers Squibb product
Contact Us for Pricing
Get competitive wholesale pricing for YERVOY 200mg. Our team is available 24/7.
Direct line: +44 7429 917553
Licensed Supplier
Authorized pharmaceutical distributor
100% Original
Guaranteed authentic products
Worldwide Delivery
International shipping available
24/7 Support
WhatsApp support anytime
How YERVOY Works
YERVOY targets CTLA-4 (cytotoxic T-lymphocyte-associated protein 4), a crucial immune checkpoint that normally acts as a "brake" on T-cell activation. Here's how it works:
**Normal Immune Regulation:** When T-cells become activated, they express CTLA-4 on their surface. CTLA-4 binds to B7 molecules on antigen-presenting cells, outcompeting the co-stimulatory receptor CD28. This sends an inhibitory signal that dampens the immune response.
**YERVOY's Mechanism:** By blocking CTLA-4, YERVOY prevents this inhibitory signal and allows CD28 to engage B7, leading to sustained T-cell activation and proliferation. This amplifies the immune response against tumor cells.
**Complementary with PD-1 Blockade:** CTLA-4 blockade enhances T-cell activation (primarily in lymph nodes), while PD-1 blockade (OPDIVO) enhances T-cell function at the tumor site. Combining both provides synergistic anti-tumor activity.
About YERVOY 200mg
YERVOY (ipilimumab) 200mg/40mL by Bristol Myers Squibb is a pioneering CTLA-4 checkpoint inhibitor that made history as the first immunotherapy to demonstrate improved overall survival in metastatic melanoma. YERVOY's approval in 2011 marked the dawn of modern cancer immunotherapy. YERVOY works by blocking CTLA-4, an immune checkpoint that normally downregulates T-cell activation. By blocking this "brake" on the immune system, YERVOY allows T-cells to mount a more vigorous anti-tumor response. Importantly, some patients treated with YERVOY achieve durable responses lasting years beyond treatment completion. While initially approved as monotherapy for melanoma, YERVOY is now most commonly used in combination with OPDIVO (nivolumab), providing dual checkpoint blockade. This combination targets both CTLA-4 and PD-1, resulting in enhanced anti-tumor activity across multiple cancer types including melanoma, renal cell carcinoma, hepatocellular carcinoma, colorectal cancer (MSI-H/dMMR), and malignant pleural mesothelioma. Pharmacy Remedy provides authentic Bristol Myers Squibb YERVOY with proper cold chain handling for oncology centers and distributors worldwide.
Common Uses
- Metastatic melanoma
- Adjuvant melanoma treatment
- Melanoma + OPDIVO combination
- Renal cell carcinoma + OPDIVO
- Hepatocellular carcinoma + OPDIVO
- MSI-H/dMMR colorectal cancer + OPDIVO
- Malignant pleural mesothelioma + OPDIVO
Dosage Information
Melanoma Monotherapy (Adjuvant):
YERVOY + OPDIVO Combinations:
*Melanoma:*
*Renal Cell Carcinoma:*
*MSI-H/dMMR Colorectal Cancer:*
*Hepatocellular Carcinoma:*
Administration:
Always consult with a qualified healthcare professional for proper dosing. This information is for reference only.
Storage & Handling
Store YERVOY vials refrigerated at 2°C to 8°C (36°F to 46°F). Protect from light. Do not freeze. Do not shake.
After dilution, store at room temperature for no more than 4 hours or refrigerated for no more than 24 hours. Discard partially used vials.
We ensure proper cold chain handling during shipping to maintain product integrity.
Frequently Asked Questions About YERVOY
Find answers to common questions about ordering, pricing, and shipping.
Related Oncology Medications Products
Explore more oncology medications medications from our catalog
